Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis.

Anna RoskillyAmy HicksEleanor J TaylorRebecca JonesRichard Parker Denis Moir

Published in: Liver international : official journal of the International Association for the Study of the Liver (2020)

The FPR in placebo-treated participants in RCTs is lower than that described from observational data. Slower fibrosis progression predicts fewer persons with NASH will progress to cirrhosis than previously estimated.

Keyphrases

double blind
electronic health record
big data
newly diagnosed
randomized controlled trial
cross sectional
machine learning